Improvement in growth after two years of growth hormone therapy in very young children born small for gestational age and without spontaneous catch-up growth: results of a multicenter, controlled, randomized, open clinical trial.
BACKGROUND
GH treatment is effective in children born small for gestational age (SGA); however, its effectiveness and safety in very young SGA children is unknown.


OBJECTIVE
The aim was to analyze the outcome of very young SGA children treated with GH and followed for 2 yr. The results after 24 months of treatment, compared with a control group without treatment during 12 months followed by 12 months of treatment, are shown.


METHODS
We performed a multicenter, controlled, randomized, open trial.


METHODS
The pediatric endocrinology departments of 14 public hospitals in Spain participated in the study.


METHODS
Seventy-six children, aged 2-5 yr born SGA and without catch-up growth, were studied.


METHODS
Children received GH at 0.06 mg/kg.d for 2 yr (group I) or were followed for 12 months with no treatment and then treated for 12 months (group II).


METHODS
Age, general health status, pubertal stage, bone age, height, weight, biochemical and hormonal analyses, and adverse side effects were determined at biannual check-ups.


RESULTS
The mean height sd score gain for chronological age in children treated for 24 months (group I) was 2.10, whereas in those treated only during the last 12 months (group II) was 1.43. In both groups, children under 4 yr of age had the greatest gain in growth velocity. No significant acceleration of bone age or side effects related to treatment was seen.


CONCLUSIONS
Very young SGA children without spontaneous catch-up growth could benefit from GH treatment because growth was accelerated and no negative side effects were observed.
Argente
Jesús
J
Department of Endocrinology, Hospital Infantil Universitario Niño Jesús, Avenida Menéndez Pelayo, 65 E28009 Madrid, Spain. argentefen@terra.es
Gracia
Ricardo
R
Ibáñez
Lourdes
L
Oliver
Antonio
A
Borrajo
Emilio
E
Vela
Amaya
A
López-Siguero
Juan Pedro
JP
Moreno
M Llanos
ML
Rodríguez-Hierro
Francisco
F
D000365:Age Determination by Skeleton; D000886:Anthropometry; D001827:Body Height / Q000187:drug effects; D015992:Body Mass Index; D002675:Child, Preschool; D005260:Female; D006128:Growth / Q000187:drug effects*; D013006:Growth Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D007236:Infant, Small for Gestational Age / Q000254:growth & development*; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008297:Male; D010290:Parents
D018972:Insulin-Like Growth Factor Binding Protein 3; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone